21 CFR § 211.192 - Production record review.

---
identifier: "/us/cfr/t21/s211.192"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 211.192 - Production record review."
title_number: 21
title_name: "Food and Drugs"
section_number: "211.192"
section_name: "Production record review."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "C"
subchapter_name: "DRUGS: GENERAL"
part_number: "211"
part_name: "CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 321, 351, 352, 355, 360b, 360ddd, 360ddd-1, 371, 374; 42 U.S.C. 216, 262, 263a, 264."
regulatory_source: "43 FR 45077, Sept. 29, 1978, unless otherwise noted."
cfr_part: "211"
---


# 211.192 Production record review.

All drug product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed. Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed. The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. A written record of the investigation shall be made and shall include the conclusions and followup.